Duovas Tablet 5mg+40mg

Duovas Tablet 5mg+40mg

Duovas is indicated for the treatment of hypertension alone or with other antihypertensive agents, to lower blood pressure. This is indicated as initial therapy in patients likely to need multiple antihypertensive agents to achieve their blood pressure goals.

Pharmacology

Amlodipine is a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. Amlodipine has a greater effect on vascular smooth muscle cells than on cardiac muscle cells.

Dosage & Administration

Substitute individually titrated components for patients on Amlodipine and Olmesartan Medoxomil. This combination may also be given with increased amounts of Amlodipine, Olmesartan Medoxomil, or both, as needed.

Interaction

The antihypertensive effect of angiotensin II receptor antagonists, including Olmesartan Medoxomil may be attenuated by NSAIDs including selective COX-2 inhibitors.

Contraindications

Cannot be co-administered with Aliskiren in patients with diabetes.

Side Effects

The most common side effects include peripheral edema, headache, flushing, and dizziness. It can also cause Intestinal problems known a sprue-like enteropathy.

Pregnancy & Lactation

Pregnancy Category D. Amlodipine and Olmesartan Medoxomil combination should not be used in 2nd and 3rd trimester because it can cause fetal death.

Precautions & Warnings

Amlodipine and Olmesartan Medoxomil combination should be used with caution because there is a risk for-

• Hypotension in volume- or salt depleted patients.
• Vasodilation in patients with severe aortic stenosis.
• Increased frequency, duration or severity of angina or acute Ml in patients with severe obstructive coronary artery disease.

Use in Special Populations

Pediatric use: The safety and effectiveness have not been established in pediatric patients. Geriatric use: No overall differences in safety or effectiveness were observed between subjects 65 years of age or older and younger subjects. Renal impairment: There are no studies in patients with renal impairment. Hepatic impairment: Initial therapy is not recommended in hepatically impaired patients.

Overdose Effects

There is no information on over dosage in humans.

Therapeutic Class

Combined antihypertensive preparations Storage Conditions Do not store above 30°C. Keep away from light and out of the reach of children.